Becton, Dickinson and Company (NYSE:BDX – Get Free Report) announced that its board has authorized a share buyback program on ...

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Becton Dickinson (BDX – Research Report), with a price ...

Piper Sandler raised the firm’s price target on Becton Dickinson (BDX) to $280 from $275 and keeps an Overweight rating on the shares. The firm ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $243.45 which represents a slight increase of $2.98 or 1.24% from the prior close of $240.47. The stock opened at $239 and ...

Atomi Financial Group Inc. lifted its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 25.3% in the ...

Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, ...

Piper Sandler's analysts increased the price target for Becton Dickinson (NYSE:BDX) shares to $280 from $275, while ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science ...

Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...